Page last updated: 2024-09-05

lapatinib and bexarotene

lapatinib has been researched along with bexarotene in 5 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(bexarotene)
Trials
(bexarotene)
Recent Studies (post-2010) (bexarotene)
1,9193051,44264267348

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)bexarotene (IC50)
Cytochrome P450 3A4Homo sapiens (human)5.9
Retinoic acid receptor RXR-alphaHomo sapiens (human)0.632
Cytochrome P450 26B1Homo sapiens (human)5.9

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Biller, BM; Tritos, NA1
Cecil, DL; Disis, ML; Gad, E; Herendeen, DR; Lai, VP; Lubet, RA; O'Meara, MM; Park, KH; Treuting, PM1
Bown, JL; Deeni, YY; Kankia, IH; Khalil, HS; Langdon, SP; Moult, PR1
Du, G; Lv, T; Ren, S; Sun, L; Wang, J; Yu, H1

Reviews

2 review(s) available for lapatinib and bexarotene

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Advances in medical therapies for Cushing's syndrome.
    Discovery medicine, 2012, Volume: 13, Issue:69

    Topics: Animals; Bexarotene; Cushing Syndrome; Etomidate; Humans; Ketoconazole; Lapatinib; Metyrapone; Mifepristone; Mitotane; Quinazolines; Somatostatin; Tetrahydronaphthalenes

2012

Other Studies

3 other study(ies) available for lapatinib and bexarotene

ArticleYear
A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease.
    Cancer prevention research (Philadelphia, Pa.), 2013, Volume: 6, Issue:12

    Topics: Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Female; Insulin-Like Growth Factor Binding Protein 2; Lapatinib; Lymphocytes, Tumor-Infiltrating; Mammary Neoplasms, Animal; Mice; Mice, Transgenic; Neoplasm Invasiveness; Precancerous Conditions; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; T-Lymphocytes; Tetrahydronaphthalenes; Tumor Cells, Cultured; Vaccines, Subunit

2013
NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.
    Oxidative medicine and cellular longevity, 2017, Volume: 2017

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; MCF-7 Cells; NF-E2-Related Factor 2; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Tetrahydronaphthalenes

2017
Bexarotene combined with lapatinib for the treatment of Cushing's disease: evidence based on drug repositioning and experimental confirmation.
    Signal transduction and targeted therapy, 2020, 08-29, Volume: 5, Issue:1

    Topics: Adrenocorticotropic Hormone; Animals; Bexarotene; Drug Combinations; Drug Repositioning; Humans; Lapatinib; Mice; Nuclear Receptor Subfamily 4, Group A, Member 1; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Protein Interaction Maps; Retinoid X Receptor alpha

2020